 LEXINGTON, Mass., March 01, 2021 GLOBE NEWSWIRE -- Kaleido Biosciences, Inc. Nasdaq: KLDO, a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Dan Menichella, President and Chief Executive Officer of Kaleido will present a corporate overview and host 1x1 meetings with investors during Chardans 3rd Annual Microbiome Medicines Summit. The presentation will take place virtually on Monday, March 8th at 9:30am-9:55am EST. 